A Cryptic Frizzled Module in Cell Surface Collagen 18 Inhibits Wnt/β−Catenin Signaling
Delphine Quélard, Elise Lavergne, Ismaïl Hendaoui et al. · 2008
Read A Cryptic Frizzled Module in Cell Surface Collagen 18 Inhibits Wnt/β−Catenin Signaling by Delphine Quélard, Elise Lavergne, Ismaïl Hendaoui et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001878.txt.
Introduction
Delphine Quelard and colleagues reported a hidden switch inside a common body protein in a 2008 PLOS ONE study. Collagens, the tough fibers that hold tissues together, can carry tucked-away parts that steer cell growth or cell death once freed. One collagen, type eighteen, comes in three forms that differ at one end.
The team studied the third form and found that it holds a part much like Frizzled, a known signal catcher. They show that this part blocks the Wnt signal path, a key route that tells cells to grow and divide. A brake built into a fiber protein is a neat find, since that path drives many cancers when stuck on.
Catalog record
| CREATOR | Delphine Quélard, Elise Lavergne, Ismaïl Hendaoui et al. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001878
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A Cryptic Frizzled Module in Cell Surface Collagen 18 Inhibits Wnt/β−Catenin Signaling Authors: Delphine Quélard, Elise Lavergne, Ismaïl Hendaoui, Harri Elamaa, Ulla Tiirola, Ritva Heljasvaara, Taina Pihlajaniemi, Bruno Clément, Orlando Musso Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001878 ABSTRACT Collagens contain cryptic polypeptide modules that regulate major cell functions, such as cell proliferation or death. Collagen XVIII (C18) exists as three amino terminal end variants with specific amino terminal polypeptide modules. We investigated the function of the variant 3 of C18 (V3C18) containing a f ri z zled module (FZC18), which carries structural identity with the extracellular cysteine-rich domain of the frizzled receptors. We show that V3C18 is a cell surface heparan sulfate proteoglycan, its topology being mediated by the FZC18 module. V3C18 mRNA was expressed at low levels in 21 normal adult human tissues. Its expression was up-regulated in fibrogenesis and in small well-differentiated liver tumors, but decreased in advanced human liver cancers. Low FZC18 immunostaining in liver cancer nodules correlated with markers of high Wnt/β−catenin activity. V3C18 (M r = 170 kD) was proteolytically processed into a cell surface FZC18-containing 50 kD glycoprotein precursor that bound Wnt3a in vitro through FZC18 and suppressed Wnt3a-induced stabilization of β−catenin. Ectopic expression of either FZC18 (35 kD) or its 50 kD precursor inhibited Wnt/β−catenin signaling in colorectal and liver cancer cell lines, thus downregulating major cell cycle checkpoint gatekeepers cyclin D1 and c-myc and reducing tumor cell growth. By contrast, full-length V3C18 was unable to inhibit Wnt signaling. In summary, we identified a cell-surface signaling pathway whereby FZC18 inhibits Wnt/β−catenin signaling. The signal, encrypted within cell-surface C18, is released by enzymatic processing as an active frizzled c ysteine- r ich d omain (CRD) that reduces cancer cell growth. Thus, extracellular matrix controls Wnt signaling through a collagen-embedded CRD behaving as a cell-surface sensor of proteolysis, conveying feedback cues to control cancer cell fate. INTRODUCTION The cell surface matrix is a signaling platform integrating bidirectional cues between cells and extracellular matrix (ECM), which contains growth factors, proteases and bioactive polypeptides, thus controlling major signaling pathways. Cryptic bioactive polypeptides become functional by structural or conformational changes of parent ECM molecules, including proteolysis [1] . Collagen XVIII (C18) [2] , [3] , the parent molecule of endostatin [4] , is expressed as three distinct variants by two separate promoters and alternative splicing of one of the transcripts [3] , [5] . Promoter #1 generates variant #1 (V1C18), which is a ubiquitous structural basement membrane component. Alternative splicing of transcripts from promoter #2 generates variants #2 (V2C18) and #3 (V3C18) [6] , [7] , which are secreted under the control of both liver-specific and ubiquitous transcription factors. V2C18 contains a 192-aa D omain of U nknown F unction-959 (DUF-959) at its N-terminus, followed by sequences common to all variants [8] . V2C18 is secreted as a plasma protein by hepatocytes [9] and its expression decreases in advanced liver cancers [10] . V3C18 carries a 235-aa stretch with 10 conserved cysteines, bearing sequence and structural identities with the extracellular c ysteine- r ich d omain (CRD) of the frizzled (FZ) receptors and the s ecreted f rizzled - r elated p roteins (SFRPs) [11] . Hence, we named this module FZC18. In the Wnt/β−catenin signaling pathway, interaction of 10 different FZ cell-surface receptors with at least 19 Wnts can be inhibited by a family of 5 SFRPs that bind to Wnts at the cell surface. In the absence of Wnt, β−catenin is recruited into a destruction complex, phosphorylated at conserved N-terminal residues by GSK3β, and thus tagged for proteasomal degradation [12] . In the nucleus, target genes of the pathway are repressed by co-repressor binding to T-cell factor (TCF) transcription factors. Wnt binding to FZ receptors blocks β-catenin phosphorylation, which becomes resistant to proteasomal degradation. Consequently, β-catenin accumulates both in the cytoplasm and the nucleus, displacing co-repressors from TCF and activating transcription of target genes that regulate the balance between proliferation and apoptosis, differentiation and metabolism, including cyclin D1, c-myc [12] and glutamine synthetase (GS) [13] . Wnt/β−catenin signaling can be activated in human cancers by oncogenic mutations or by epigenetic silencing of pathway components. Respectively, 85% and 10% of sporadic colorectal cancers (CRCs) have APC and β−catenin mutations [12] . Epigenetic inactivation of SFRP genes occurs early in CRC [14] and restoring SFRP expression attenuates Wnt/β−catenin signaling [15] . In 30–40% of human hepatocellular carcinomas (HCCs), activation of the pathway results from β−catenin and axin mutations [16] or epigenetic silencing of SFRP1 [17] . We investigated whether FZC18 could regulate Wnt/β−catenin signaling. We show that V3C18 mRNA expression decreases in advanced HCCs. In addition, the N-terminus of the V3C18 is partially processed to a FZC18 precursor (V3Nter) which pulls down Wnt3a in vitro , suppresses Wnt/β−catenin signaling and downstream gene expression, reduces tumor cell growth and increases cell death in CRC and HCC cell lines carrying activating β−catenin mutations. The biological activity of FZC18 is cryptic within full-length C18, as it is activated by proteolytic release. RESULTS We analyzed the mRNA levels of V3C18 in human tissues by QRT-PCR (quantitative RT-PCR) using brain as a calibrator ( Figure 1B ). V3C18 showed the highest levels in kidney, followed by liver, placenta, lung, bone marrow and testis. The expression of V3C18 was 2 to 14 folds lower in cell lines from human HCC, CRC, breast cancer or embryonic kidney than in normal liver ( Figure 1C ). In addition, in the well-differentiated mouse hepatoma cell line mhAT3FS315, carrying a dominant negative form of the HNF3 transcription factor, inhibiting expression of genes controlling the hepatocyte phenotype [18] , the expression of V3C18 mRNA was 22% of that in the parental cell line mhAT3F ( Figure 1C ). (A) Schematic of V3C18 showing DUF-959, FZC18, Tsp-1 (thrombospondin-1) and ES (endostatin) modules. The thick horizontal yellow line below FZC18 indicates the probe used. (B–D) Relative mRNA expression of V3C18 by QRT-PCR in human tissues (Human Total RNA Master Panel, Clontech, USA) (B) and in cell lines (C). Assays were performed in triplicate with a coefficient of variation <10% and normalized to 18S. Brain (B) and liver (C) were used as calibrators. (D) Relative V3 mRNA expression in human liver samples. Small (≤2 cm), well-differentiated HCCs are compared to advanced HCCs. mRNA samples were blotted in triplicates onto nylon membranes and arrays hybridized with 32 P-labeled cDNA under linear-range conditions. Densitometry readings were normalized with an 18S probe. Bar graphs show mean±SD. The Mann Whitney's “U” test was used. NS, non significant; NT, non tumor livers. Low expression of V2C18 is associated with tumor progression and reduced disease-free survival in HCCs [10] . Although V2C18 and V3C18 share a common promoter, V3C18 is additionally regulated by alternative splicing of FZC18 to produce V2 [7] . Analysis of mRNA arrays from 122 frozen liver samples included normal livers from 19 subjects, 54 HCCs and 49 matching non tumor livers. V3C18 mRNA levels were higher in fibrotic and cirrhotic livers than in normal livers ( Figure 1D ), indicating that the expression of V3C18 increases during tissue remodeling. Small (≤2 cm) well-differentiated HCCs showed higher V3C18 mRNA levels than advanced HCCs. The mean±SD size of both groups was 1.3±0.38 cm and 6.5±4.6 cm,